$775 Million is the total value of Kynam Capital Management, LP's 35 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 38.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NTRA | Buy | NATERA INC | $162,020,518 | +54.9% | 2,918,237 | +12.1% | 20.92% | +30.4% |
| HZNP | Sell | HORIZON THERAPEUTICS PUB L | $119,466,827 | -4.6% | 1,094,620 | -0.5% | 15.42% | -19.7% |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $67,710,424 | +3.9% | 3,205,986 | +25.2% | 8.74% | -12.6% |
| CLDX | Sell | CELLDEX THERAPEUTICS INC NEW | $50,712,047 | -29.1% | 1,409,451 | -12.2% | 6.55% | -40.4% |
| PCVX | Buy | VAXCYTE INC | $45,605,064 | +35.2% | 1,216,784 | +73.0% | 5.89% | +13.8% |
| New | 2SEVENTY BIO INC | $38,137,514 | – | 3,738,972 | +100.0% | 4.92% | – | |
| TVTX | Buy | TRAVERE THERAPEUTICS INC | $35,165,252 | +299.9% | 1,563,595 | +274.0% | 4.54% | +236.5% |
| PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $31,625,000 | +456.5% | 1,375,000 | +164.0% | 4.08% | +368.1% |
| VERA | Buy | VERA THERAPEUTICS INCcl a | $26,170,041 | -4.0% | 3,372,428 | +139.3% | 3.38% | -19.2% |
| BNR | Buy | BURNING ROCK BIOTECH LTDsponsored ads | $22,537,956 | +35.5% | 8,020,625 | +8.5% | 2.91% | +14.0% |
| SGEN | New | SEAGEN INC | $20,247,000 | – | 100,000 | +100.0% | 2.61% | – |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $18,584,535 | +114.6% | 499,853 | +161.5% | 2.40% | +80.5% |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $18,000,000 | +54.3% | 12,000,000 | +24.5% | 2.32% | +29.8% |
| Sell | GSK PLCsponsored adr | $17,730,546 | +0.6% | 498,329 | -0.7% | 2.29% | -15.3% | |
| WVE | Buy | WAVE LIFE SCIENCES LTD | $16,488,103 | +90.2% | 3,807,876 | +207.5% | 2.13% | +60.0% |
| VRDN | Sell | VIRIDIAN THERAPEUTICS INC | $13,829,260 | -54.2% | 543,603 | -47.5% | 1.78% | -61.5% |
| LQDA | Sell | LIQUIDIA CORPORATION | $11,347,906 | +1.6% | 1,642,244 | -6.3% | 1.46% | -14.5% |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INC | $10,998,000 | – | 1,800,000 | +100.0% | 1.42% | – |
| BCRX | New | BIOCRYST PHARMACEUTICALS INC | $8,340,000 | – | 1,000,000 | +100.0% | 1.08% | – |
| ALLO | Buy | ALLOGENE THERAPEUTICS INC | $7,390,146 | +196.4% | 1,495,981 | +277.4% | 0.95% | +149.7% |
| OLMA | Sell | OLEMA PHARMACEUTICALS INC | $6,981,130 | +40.7% | 2,011,853 | -0.7% | 0.90% | +18.4% |
| MCRB | Sell | SERES THERAPEUTICS INC | $4,359,737 | +0.2% | 768,913 | -1.0% | 0.56% | -15.6% |
| COGT | Sell | COGENT BIOSCIENCES INC | $4,315,719 | -53.0% | 399,974 | -49.6% | 0.56% | -60.4% |
| STRO | Buy | SUTRO BIOPHARMA INC | $4,166,482 | +27.5% | 901,836 | +122.9% | 0.54% | +7.4% |
| CNTA | Sell | CENTESSA PHARMACEUTICALS PLCsponsored ads | $2,806,946 | +23.4% | 729,077 | -0.7% | 0.36% | +3.7% |
| GOSS | Sell | GOSSAMER BIO INC | $1,893,611 | -50.7% | 1,502,866 | -15.2% | 0.24% | -58.6% |
| ARGX | New | ARGENX SEput | $1,676,610 | – | 4,500 | +100.0% | 0.22% | – |
| RYTM | New | RHYTHM PHARMACEUTICALS INC | $1,652,020 | – | 92,602 | +100.0% | 0.21% | – |
| PBYI | Sell | PUMA BIOTECHNOLOGY INC | $1,461,786 | -38.5% | 473,070 | -15.8% | 0.19% | -48.1% |
| XENE | Sell | XENON PHARMACEUTICALS INC | $1,027,030 | -9.8% | 28,696 | -0.7% | 0.13% | -24.0% |
| New | ARCELLX INC | $965,462 | – | 31,336 | +100.0% | 0.12% | – | |
| CNTB | CONNECT BIOPHARMA HLDGS LTDads | $739,575 | +15.2% | 739,649 | 0.0% | 0.10% | -3.1% | |
| MRUS | New | MERUS N V | $394,809 | – | 21,457 | +100.0% | 0.05% | – |
| NLTX | Sell | NEOLEUKIN THERAPEUTICS INC | $83,976 | +36.6% | 119,966 | -0.7% | 0.01% | +22.2% |
| CBIO | Sell | CATALYST BIOSCIENCES INC | $18,606 | -61.0% | 89,886 | -0.7% | 0.00% | -71.4% |
| CABA | Exit | CABALETTA BIO INC | $0 | – | -165,486 | -100.0% | -0.24% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INC | $0 | – | -300,000 | -100.0% | -2.38% | – |
| CNCE | Exit | CONCERT PHARMACEUTICALS INC | $0 | – | -4,420,349 | -100.0% | -3.96% | – |
| UTHR | Exit | UNITED THERAPEUTICS CORP DEL | $0 | – | -100,000 | -100.0% | -4.27% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SYNDAX PHARMACEUTICALS INC | 8 | Q3 2023 | 12.3% |
| CELLDEX THERAPEUTICS INC NEW | 8 | Q3 2023 | 14.4% |
| VAXCYTE INC | 8 | Q3 2023 | 10.9% |
| VERA THERAPEUTICS INC | 8 | Q3 2023 | 6.9% |
| TRAVERE THERAPEUTICS INC | 8 | Q3 2023 | 7.6% |
| VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 4.6% |
| BURNING ROCK BIOTECH LTD | 8 | Q3 2023 | 3.4% |
| AMARIN CORP PLC | 8 | Q3 2023 | 4.0% |
| LIQUIDIA CORPORATION | 8 | Q3 2023 | 3.6% |
| WAVE LIFE SCIENCES LTD | 8 | Q3 2023 | 3.7% |
View Kynam Capital Management, LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-03-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-01-10 |
View Kynam Capital Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.